{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010046","form_type":"8-K","ticker":null,"cik":"0001460602","company_name":"Orgenesis Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.086198+00:00","generated_at":"2026-06-17T07:45:52.351437+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Orgenesis subsidiary Koligo enters $5M convertible loan with Yehuda Nir at 8% interest","bullets":["Loan up to $5M from lender Yehuda Nir to subsidiary Koligo Therapeutics; 8% annual interest, maturity Jan 1, 2024.","Mandatory conversion at 50% discount per share if Koligo completes a qualified equity financing of at least $5M by Dec 31, 2023.","Lender may assign $1.5M of existing Orgenesis loan to Koligo under original terms (10% interest, maturity Jan 31, 2026).","Proceeds to be used for working capital; events of default include bankruptcy, material breach, and payment failure."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010046","json":"https://secwatch.observer/filing/0001493152-23-010046.json","markdown":"https://secwatch.observer/filing/0001493152-23-010046.md","text":"https://secwatch.observer/filing/0001493152-23-010046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460602/000149315223010046/0001493152-23-010046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460602/000149315223010046/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:45:52.351437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c957a9f1529e6d11ee36604031791d7180ea1d8","claim":"Orgenesis Inc. incurred convertible notes of up to $5,000,000 with Yehuda Nir at 8% per annum maturing January 1, 2024.","evidence_excerpt":"On March 27, 2023, Koligo Therapeutics Inc. (“Borrower”), a subsidiary of Orgenesis Inc. (the “Company”) entered into a convertible loan agreement (the “Convertible Loan Agreement”) with Yehuda Nir (the “Lender,” and together with the Borrower, the “Parties”), pursuant to which the Lender agreed to loan the Borrower up to $5,000,000 (the “Loan Amount”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460602/000149315223010046/0001493152-23-010046-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"up to $5,000,000"},{"label":"Counterparty","value":"Yehuda Nir"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"January 1, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"79865eb38cb62e3b0c359e53630f8f67ec71e46f","claim":"Orgenesis Inc. entered into Convertible Loan Agreement with Yehuda Nir valued at Loan up to $5,000,000, interest at 8% per annum, maturity date January 1, 2024 (effective 2023-03-27).","evidence_excerpt":"On March 27, 2023, Koligo Therapeutics Inc. (“Borrower”), a subsidiary of Orgenesis Inc. (the “Company”) entered into a convertible loan agreement (the “Convertible Loan Agreement”) with Yehuda Nir (the “Lender,” and together with the Borrower, the “Parties”), pursuant to which the Lender agreed to loan the Borrower up to $5,000,000 (the “Loan Amount”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460602/000149315223010046/0001493152-23-010046-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Yehuda Nir"},{"label":"Value","value":"Loan up to $5,000,000, interest at 8% per annum, maturity date January 1, 2024"},{"label":"Effective","value":"2023-03-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}